Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,711,700 | 2,107,457 | 1,440,023 | 602,753 | 1,176,800 |
| Depreciation Amortization | 109,500 | 80,160 | 53,518 | 26,821 | 106,900 |
| Income taxes - deferred | 277,300 | 65,110 | 8,963 | 36,705 | 167,400 |
| Accounts receivable | -223,400 | -151,191 | -164,139 | -223,672 | -225,600 |
| Accounts payable and accrued liabilities | 51,300 | 16,153 | 14,697 | 14,285 | -22,800 |
| Other Working Capital | -54,400 | 252,707 | 156,835 | -22,425 | -66,100 |
| Other Operating Activity | 381,500 | 391,577 | 344,328 | 381,231 | 432,700 |
| Operating Cash Flow | $3,253,500 | $2,761,973 | $1,854,225 | $815,698 | $1,569,300 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -259,800 | -212,109 | -37,314 | -19,450 | -75,400 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -1,154,200 |
| Purchase Of Investment | -450,700 | -266,264 | -132,377 | -81,065 | -537,200 |
| Sale Of Investment | 809,900 | 334,014 | 273,269 | 132,181 | 570,800 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -39,300 |
| Investing Cash Flow | $99,400 | $-144,359 | $103,578 | $31,666 | $-1,235,300 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 13,300 | 8,642 | 5,833 | 5,833 | 10,000 |
| Debt Repayment | -42,300 | -31,378 | -20,730 | -10,287 | -39,200 |
| Common Stock Issued | 264,900 | 234,854 | 213,058 | 79,597 | 343,200 |
| Common Stock Repurchased | -539,100 | -408,033 | -300,026 | -300,026 | -186,000 |
| Other Financing Activity | -202,100 | -184,174 | -137,540 | -134,547 | -1,200 |
| Financing Cash Flow | $-505,300 | $-380,089 | $-239,405 | $-359,430 | $126,800 |
| Exchange Rate Effect | 20,600 | 2,779 | -3,379 | -6,651 | 1,600 |
| Beginning Cash Position | 3,120,700 | 3,120,681 | 3,120,681 | 3,120,681 | 2,658,300 |
| End Cash Position | 5,988,900 | 5,360,985 | 4,835,700 | 3,601,964 | 3,120,700 |
| Net Cash Flow | $2,868,200 | $2,240,304 | $1,715,019 | $481,283 | $462,400 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,253,500 | 2,761,973 | 1,854,225 | 815,698 | 1,569,300 |
| Capital Expenditure | -259,800 | -212,109 | -37,314 | -19,450 | -75,400 |
| Free Cash Flow | 2,993,700 | 2,549,864 | 1,816,911 | 796,248 | 1,493,900 |